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New fluoroethyl phenylalanine 
analogues as potential LAT1-
targeting PET tracers for 
glioblastoma
Jeroen Verhoeven  1, Fabian Hulpia2, Ken Kersemans3, Julie Bolcaen3, Stef De Lombaerde1, 
Jan Goeman4, Benedicte Descamps  5, Giorgio Hallaert6, Caroline Van den Broecke7, 
Karel Deblaere8, Christian Vanhove5, Johan Van der Eycken4, Serge Van Calenbergh  2, 
Ingeborg Goethals3 & Filip De Vos1
The use of O-(2-[18F]fluoroethyl)-l-tyrosine ([18F]FET) as a positron emission tomography (PET) tracer 
for brain tumor imaging might have some limitations because of the relatively low affinity for the L-type 
amino acid transporter 1 (LAT1). To assess the stereospecificity and evaluate the influence of aromatic 
ring modification of phenylalanine LAT1 targeting tracers, six different fluoroalkylated phenylalanine 
analogues were synthesized. After in vitro Ki determination, the most promising compound, 2-[18F]-2-
fluoroethyl-l-phenylalanine (2-[18F]FELP), was selected for further evaluation and in vitro comparison 
with [18F]FET. Subsequently, 2-[18F]FELP was assessed in vivo and compared with [18F]FET and [18F]FDG 
in a F98 glioblastoma rat model. 2-[18F]FELP showed improved in vitro characteristics over [18F]Fet, 
especially when the affinity and specificity for system L is concerned. Based on our results, 2-[18F]FELP 
is a promising new PET tracer for brain tumor imaging.
In neuro-oncology, the potential of conventional magnetic resonance imaging (MRI) to differentiate neoplastic 
tissue from non-specific changes induced by treatment may be limited after therapeutic interventions (e.g. radi-
ation therapy, neurosurgical resection, and chemotherapy). The molecular imaging modality positron emission 
tomography (PET) provides additional information on tumor metabolism, which allows for more accurate diag-
nostics and therapy response assessment1–3. During the last decades, a variety of molecular targets have been 
assessed for brain tumor imaging by specific PET tracers. Especially amino acid (AA) based tracers received a 
lot of attention2,4. In contrast to [18F]fluoro-2-deoxy-d-glucose ([18F]FDG, Fig. 1), the uptake of radiolabeled 
AAs is low in normal gray matter of the brain which results in higher tumor-to-background ratios5. A con-
siderable advantage of AA over nucleoside- or choline-based tracers is the ability to pass through the intact 
blood-brain barrier (BBB) due to the presence of AA transporters. The transport of AA into cells is mediated 
by specific membrane associated carrier proteins, which are classified into different transporter systems based 
on criteria such as sodium dependence, substrate specificity, kinetics, etc.6. Amongst the currently known AA 
transporters, system L and system ASC are overexpressed in most tumor tissues, rendering these convenient 
targets for metabolic imaging of tumor cells7–9. The most widespread 18F labeled tracers that have been devel-
oped are O-(2-[18F]fluoroethyl)-l-tyrosine ([18F]FET) and 3, 4-dihydroxy-6-[18F]-fluoro-l-phenylalanine ([18F]
FDOPA; Fig. 1). Unfortunately, both are not specific for the L-type amino acid transporter 1 (LAT1) and the latter 
shows uptake in the striatum due to participation in the dopamine synthesis pathway10–13. Most of the amino 
acid PET tracers, including [18F]FET, still suffer from various levels of physiological background uptake and 
uptake in non-neoplastic lesions such as acute inflammatory lesions as a result from multiple sclerosis or brain 
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abscesses14–17. An advantage of these non-natural amino acid tracers is the insusceptibility to in vivo metabo-
lism resulting in the absence of radiolabeled metabolites18. Different PET and single-photon emission computed 
tomography (SPECT) tracers based on tyrosine, tryptophan and glutamine have been developed for LAT1 or 
ASCT2 targeting19–22, of which the most promising results have been reported for 3-fluoro-l-α-methyltyrosine 
([18F]FAMT, Fig. 1). However, the existing synthetic methods for the preparation of [18F]FAMT suffer from low 
chemical yields, which limits the availability of this tracer for clinical use23,24. Based on the structure of [18F]FET, 
Wang et al. have developed para-fluoroethyl (15 & 16, Fig. 1) and -fluoropropyl alkylated phenylalanine deriva-
tives, where the former showed appreciable uptake in the 9 L glioma tumor model25.
In this study we want to develop a practical synthesis for different phenylalanine derivatives and compare 
their affinity for the LAT1 transporter. As there are conflicting reports on the preferred stereochemistry of the 
phenylalanine/tyrosine analogues for the LAT1 transporter26–28, both enantiomers (S) and (R) of ortho- (32 & 33) 
and meta- (17 & 18) substituted 2-fluoroethyl phenylalanine derivatives (Fig. 1) were synthesized and their Ki was 
determined in LAT1 overexpressing F98 glioblastoma (GB) cells29. Previously reported para-substituted deriv-
atives (15 & 16) were included to allow comparison with the novel analogs in our in vitro system. The in vitro 
uptake of the most promising compound was compared to [18F]FET and its uptake in a rat F98 GB model was 
evaluated.
Results
Chemistry. Initially, we set out to employ a common starting material (1 & 2, Fig. 2) to gain access to all 
the different (ortho-, meta- and para-) substituted phenylalanine amino acids. This approach was inspired by 
recent work of the Baran group, which described arylation of activated glutamate esters with boronic acids under 
Ni-catalysis30. This route could enable access to all different phenylalanine derivatives from a single amino acid 
precursor.
The synthesis started from suitably protected commercially available l- or d-aspartic acid derivatives (Fig. 2). 
After activation of the side chain carboxylic acid as a N-hydroxytetrachlorophtalimide ester, 1 or 2 was reacted 
with the corresponding boronic acids (21 (para) or 22 (meta)) to give the substituted phenylalanine derivatives 
3–6 in acceptable yields. The preparation of boronic acid derivatives is depicted in Fig. 3. Commercially available 
bromo-phenylethanol was protected with TBSCl and subsequently transformed into the corresponding boronic 
acid by Li/Br exchange and trapping with trimethylborate31,32.
With the boronic acids in hand, cross-coupling was found successful for the synthesis of both para- and meta- 
substituted derivatives (Fig. 2). Next, the primary alcohol was unmasked by TBAF in THF, and fluorinated with 
DAST and deprotected to give rise to the fluorinated amino acids 15–18.
Attempts were made to prepare the ortho-substituted derivatives (32 & 33, Fig. 4) with the same strategy, 
however, this was met with several issues. Firstly, the preparation of TBS-protected ortho-boronic acid was 
troublesome, as the major product observed was the corresponding oxaborole (data not shown). This could 
be circumvented by employing the corresponding TIPS-protected alcohol. Next, the cross-coupling reac-
tion with the ortho-substituted boronic acid failed to give appreciable amount of the coupled product, proba-
bly due to steric hindrance. This was confirmed by attempting the same reaction with commercially available 
2-ethylphenylboronic acid and activated amino acid ester 1 under the same reaction conditions without success. 
Then, attempts with altered reaction conditions (temperature, catalyst loading and/or catalytic system (bathophe-
nanthroline30 instead of 4, 4′-di-tert-butyl-2, 2′-dipyridyl, BBBPY)) also did not deliver the desired product (data 
not shown). Therefore, it was decided to switch to another synthetic route, employing a pre-functionalized phe-
nylalanine starting material (Fig. 4).
This synthetic approach was based on the literature route described for the synthesis of para-substituted phe-
nylalanine amino acids25,28. Commercially available N-Boc-2-bromophenylalanine was protected as its tert-butyl 
ester with t-butyl 2, 2, 2-trichloroacetimidate (TBTA) and vinylated with a Stille coupling reaction to give 25 and 
26. Next, hydroboration introduced the primary alcohol, which was either fluorinated and deprotected to give 
Figure 1. Structures of clinically used radiotracers or previously described amino acid tracers (upper part). 
Structures of the prepared modified phenylalanine analogs in this manuscript (lower part).
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the free amino acids 2-FELP (32) and 2-FEDP (33), or tosylated with tosylchloride to give 31 to serve as radiola-
belling precursor.
In vitro experiments. Flow cytometry. The expression of LAT1 in the F98 cells was confirmed by flow 
cytometry (Supplementary Fig. 4).
Concentration dependency using [2, 3, 4, 5, 6-3H]-l-phenylalanine. The affinity constant Ki of all compounds for 
the system L transporters was determined to identify the optimal derivatization position on the phenyl ring, as 
well as the preferred stereochemistry for system L targeting. The Ki-values are shown in Table 1 and representable 
Km and Km,app charts are shown in Fig. 5 (see also Supplementary Information). Between all compounds a statisti-
cally significant difference was found (p = 0.002), except between 3FEDP–3FELP and 3FEDP–4FELP (p = 0.065 
and 0.485 respectively).
Radiochemistry. [18F]FET and 2-[18F]FELP were prepared as described below. Enantiomerically pure 
(ee > 99%) 2-[18F]FELP was synthesized in 90 min with high radiochemical purity (>95% as measured by ana-
lytical HPLC and TLC), good yield (10–30% with respect to the starting activity at the end of F18 production, 
not corrected for decay), and high molar activity (243.7 ± 11.9 GBq/µmol). Chromatograms can be found in the 
Supplementary Information.
2-[18F]FELP exhibits a logPoct value of −1.16 ± 0.011 which is in accordance with the logPoct value of phenyla-
lanine (logPoct = −1.38)33 while a logPoct value of −1.48 ± 0.047 was observed for [18F]FET.
Concentration and time dependency using 2-[18F]FELP or [18F]FET. Since the lowest Ki-value was obtained for 
2-FELP, the uptake characteristics of this tracer were investigated further and compared with the uptake charac-
teristics of FET (Fig. 6). The maximum uptake of [18F]FET, used as a reference, and 2-[18F]FELP was studied in 
F98 cells. The latter compound seemed more sodium dependent than [18F]FET (44% vs 36% more uptake in pres-
ence of Na+). BCH, a system L and b0,+ inhibitor, blocked the 2-[18F]FELP or [18F]FET uptake by >99% and 97%, 
respectively. In the presence of the system A inhibitor, MeAiB, 2-[18F]FELP was inhibited less (51.5% less uptake) 
Figure 2. Reagents and conditions: a) TCNHPI, DIC, DCM, rt, 59% (1), 70% (2); b) Boronic acid (21 or 22), 
NiCl2.6H2O, BBBPY, Et3N, DMF/1, 4-dioxane (1/10), 75 °C, overnight, 46% (3 & 4), 59% (5), 34% (6); c) 1 M TBAF 
in THF/THF, rt, 83% (7), 77% (8), 71% (9), 73% (10); d) DAST, DCM, 0 °C–rt, 42% (11), 37% (12), 50% (13), 29% 
(14); e) TFA/DCM (1/1), rt, 39% (4-FELP, 15), 35% (4-FEDP, 16), 46% (3-FELP, 17), 46% (3-FEDP, 18).
Figure 3. Reagents and conditions: a) TBSCl, imidazole, DMF, 98% (19), quant. (20); b) i. n-BuLi (1.6 M in 
hexanes), THF, −78 °C; ii. B(OMe)3, −78 °C–rt; iii. aq. HCl, 42% (21), 55% (22).
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than that of [18F]FET (95% less uptake). The most interesting difference was observed by studying the effect of 
the recently developed LAT1 specific inhibitor JPH203, which inhibited the uptake of [18F]FET by 65% and that 
of 2-[18F]FELP by >99%. Statistical analysis showed a significant difference between the uptake in HEPES+ 
buffer and HEPES-/BCH/MeAiB/JPH203 (p = 0.002) and between BCH and MeAiB (p = 0.002) for both tracers. 
However, no difference could be found when the BCH and JPH203 uptake of 2-[18F]FELP (p = 0.065) was com-
pared to [18F]FET (p = 0.002). These data indicate that LAT1 is more involved in the 2-[18F]FELP than in the [18F]
FET uptake. The uptake in V0 conditions of both 2-[18F]FELP and [18F]FET as a function of the concentration 
of non-radioactive analogue (0.01–0.5 mM) was saturable following the Michaelis-Menten equation. The related 
Michaelis-Menten plot resulted in a Km value (expressed in µM, mean ± SD, n = 6) of 12.54 ± 3.82 µM for 2-[18F]
FELP and 312.9 ± 25.6 µM for [18F]FET. Moreover, the Km values were not significantly different from their cor-
responding Ki values determined earlier (2-[18F]FELP: p = 0.165; [18F]FET: p = 0.558).
In vivo experiments. Two weeks after inoculation of F98 cells, tumors were visible in the right frontal region 
of rats on T2-weighted and contrast-enhanced T1-weighted MRI (Fig. 7). Hematoxylin and eosin stained paraffin 
sections revealed tumor necrosis, microvascular proliferation, nuclear atypia and increased mitosis, confirming 
the presence of GB (Fig. 8)11,34.
Semi-quantitative analysis. The SUVmean, SUVmax, TBRmean and TBRmax were calculated for the differ-
ent radiotracers (Fig. 9). No significantly different TBR and SUV values were found between 2-[18F]FELP and 
[18F]FET PET (TBRmean: p = 0.386; TBRmax: p = 0.773; SUVmean: p = 0.0830; SUVmax: p = 1.00). Significant differ-
ences were observed between 2-[18F]FELP and [18F]-FDGearly (TBRmean: p = 0.043; TBRmax: p = 0.021; SUVmean: 
p = 0.021), [18F]FET and [18F]FDGearly (TBRmean: p = 0.021; TBRmax: p = 0.021), [18F]FET and [18F]FDGlate 
(TBRmean: p = 0.021; SUVmean: p = 0.043), [18F]FDGearly and [18F]FDGlate (TBRmax: p = 0.043; SUVmean: p = 0.043). 
The TBRmean values of the dynamic scans are shown in Fig. 10. The TBRmean values of [18F]FDG PET scans were 
significantly lower in comparison with the 2-[18F]FELP and [18F]FET (p = 0.043 and 0.021 respectively). No sig-
nificant differences were found between the AA PET scans (p = 0.386).
Discussion
The L-type AA transporter 1 transports aromatic or branched AA that are essential for cellular proliferation and 
growth. Due to its low expression and distribution in non-pathological cells and upregulation in glioma cells, this 
AA transporter received a lot of attention as potential target for tumor imaging1,13. Molecular imaging using PET 
may provide relevant additional information on tumor metabolism and may be useful in case of ambiguous MRI 
findings following neuro-oncological treatment35. In this study, two recently developed fluoroalkyl phenylalanine 
analogues, 4-FELP and 4-FEDP25, together with four new compounds, 2-FELP, 2-FEDP, 3-FELP, 3-FEDP were 
Figure 4. Reagents and conditions: a) TBTA, DCM, overnight, 90% (23), 72% (24); b) vinyl-Sn(nBu)3, LiCl, 
Pd(Ph3P)2Cl2, DMF, 70 °C, overnight, 51% (25), 67% (26); c) i. BH3.THF, THF, 0 °C–rt; ii. NaBO3.H2O, water, rt, 
66% (27), 61% (28); d) DAST, DCM, 0 °C–rt, 45% (29), 54% (30); e) Tosylchloride, DMAP, Et3N, DCM, rt, 56% 
(31); f) TFA/DCM (1/1), rt, 23% (2-FELP, 32), 49% (2-FEDP, 33); g) i. [18F]F−/Kryptofix®222/K+ complex, 
MeCN, 100 °C, 15 min, ii. 2 M aq. HCl, 15 min, iii. 4 M aq. NaOH, iv. HPLC purification.
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successfully synthesized and compared in vitro to the reference compound FET, currently used in the clinic. The 
influence of the stereochemistry on the affinity for the LAT1 transporter was evaluated as there are some conflict-
ing reports in literature. When comparing 123/125I-labelled 2-iodo-l-phenylalanine and 2-iodo-d-phenylalanine 
in R1M cells26, Kersemans et al. observed a high affinity of the LAT transporter for the d-enantiomer, while 
Bauwens et al.27 reported a higher Ki values for d-tyrosine than for 2-I-l-tyrosine. In this study, the in vitro affinity 
of the d-enantiomers for the LAT1 transporter in F98 GB cells was lower than the affinity of the l-enantiomers, 
except for the meta-substituted enantiomers. This promiscuity regarding the (stereochemical) substrate prefer-
ence was observed in a recent publication as well36. When considering the Ki values of the l-enantiomers, the 
Compound Ki value (µM) Compound Ki value (µM)
16.09 ± 3.74 359.40 ± 47.10
48.95 ± 4.92 83.75 ± 28.10
85.55 ± 4.40 >2000
307.20 ± 4.29 51.53 ± 7.80
Table 1. Ki values (expressed in µM, mean ± SD, n = 6) of the ortho-, meta- and para- substituted compounds, 
FET and l-phenylalanine.
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Figure 5. Left: Concentration dependence uptake of [3H]-l-Phe. Right: Concentration dependence of [3H]-l-
Phe uptake in presence of 3-FELP. A 1-min incubation time was used. Michaelis-Menten plots were obtained to 
calculate Km (left) and Km,app (right).
Figure 6. Maximum uptake of [18F]FET and 2-[18F]FELP in presence of sodium free (HEPES-) or sodium rich 
buffer (HEPES+) and supplemented with transporter specific inhibitors. Inhibitors: BCH for system L and b0,+, 
MeAiB for system A, JPH203 for LAT1 (expressed as % uptake/µg protein, mean ± SD, n = 6).
Figure 7. µPET images (upper row) and contrast-enhanced T1-weighted MRI (bottom row) of GB in rats. A high 
heterogeneous tumor uptake was visible on 2-[18F]FELP (A) and [18F]FET PET (B) (100–120 min post-injection) 
with a relative low uptake in healthy brain tissue. Both [18F]FDG PET scans, 60 min (C) and 240 min post-injection 
(D), showed a homogeneous intense uptake in the tumor, however, a higher uptake the in surrounding normal 
brain tissue can be noted. The latter is clearly lower on the delayed [18F]-FDG PET scan (D).
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Figure 8. Hematoxylin and eosin stained paraffin sections of the rat brain confirming the presence of GB 
characteristics: High cellularity and nuclear pleiomorphism (a), microvascular proliferation and tumor necrosis 
(b), visible tumor infiltration with vessel recruitment at rim of tumor (c).
Figure 9. Comparison of the TBRmean, TBRmax, SUVmean and SUVmax in F98 GB tumor between 2-[18F]FELP, 
[18F]FET and [18F]FDG PET. *p value < 0.05.
Figure 10. The TBRmean values of the dynamic 2-[18F]FELP and [18F]FET PET scans were significantly higher in 
comparison with [18F]FDG. No significant differences were found between the AA PET scans.
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preference of the position of the 2-fluoroethyl substituent on the aromatic ring of phenylalanine was as follows: 
ortho > meta > para.
Based on earlier studies36,37, it has been shown that meta-substitution appears to be the most tolerant towards 
substitution. Therefore, it is quite remarkable that the ortho-substituted 2-FELP displays the highest in vitro 
affinity.
The radiofluorinated 2-[18F]FELP and [18F]FET were successfully prepared on a Synthra RN plus module 
using identical reaction and purification conditions. The relatively straightforward synthesis method, as described 
earlier, simplifies the availability for clinical use, which has been an issue for [18F]FAMT38.
In the present study, the in vitro influx of 2-[18F]FELP and [18F]FET was characterized in F98 GB cells by 
means of inhibition experiments, involving the recently identified selective LAT1 inhibitor JPH203, which has 
structural analogy to tyrosine. Moreover, this compound effectively inhibits the proliferation of various tumor 
cells injected into nude mice39. The uptake of 2-[18F]FELP was considerably lower in presence of the inhibitor 
JPH203 compared to the uptake of [18F]FET. This indicates that 2-[18F]FELP is predominantly transported by 
the LAT1 transporter. The results for [18F]FET are in conformity with the study conducted by Langen et al.40 and 
the limited inhibition by JPH203 could be explained by LAT2 non-specific uptake, which has been described 
earlier in F98 cells41. As LAT1 overexpression has been correlated with malignant phenotype and proliferation of 
gliomas, our in-house developed AA could possibly demonstrate value for guiding biopsy, diagnosing primary 
brain tumor, tumor grading, directing radiotherapy, or even for discriminating between tumor recurrence and 
radionecrosis post-therapy42,43.
In a second set of in vitro experiments, the Km was determined by means of a concentration dependent assay. 
The results show a saturable transport consistent with Michaelis Menten kinetics. The Ki of 2-[18F]FELP and [18F]
FET did not differ significantly from their Km values. The Ki value of a competitive inhibitor of a transport process 
of a substrate is equal to the Km value for transport of the inhibitor by the same process. Therefore, the determina-
tion of Ki values can be particularly useful if no radioactive labeled compound is available44.
Using an in vivo orthotopic tumor model, the uptake of different AA tracers were compared with [18F]FDG 
uptake characteristics. As described in literature, the AA tracers benefit from a lower background signal, resulting 
in increased tumor-to-background values3. However, no significant differences could be observed between 2-[18F]
FELP and [18F]FET. The elevated uptake of both tracers in the GB model could be enhanced by BBB breakdown45. 
We hypothesize that the uptake in low grade glioma, where the BBB is intact and the LAT1 expression is less 
distinct, would give rise to different time activity curves as seen by Galldiks et al.46. Unfortunately, preclinical low 
grade glioma models are not widely available47.
In summary, 2-[18F]FELP has a better affinity and selectivity for the LAT1 transporter compared to [18F]FET, 
decreasing non-specific tumor uptake. As LAT1 overexpression has been correlated with malignant phenotype 
and proliferation of gliomas, this new AA tracer could possibly demonstrate value for guiding biopsy, diagnosing 
primary brain tumor, tumor grading, directing radiotherapy, or even for discriminating between tumor recur-
rence and radionecrosis after initial therapy42,43.
Conclusion
In this study we synthesized six fluoroalkyl substituted phenylalanine analogues, of which four have not been 
described before. The affinity of the d-enantiomers for the LAT1 transporter in F98 GB cells was lower than the 
affinity of the l-enantiomers. 2-FELP exhibits the best affinity for the F98 GB cells. Radiolabeling was performed 
on a Synthra RN plus module, following the same straightforward method as for [18F]FET. In vitro uptake and 
inhibition experiments showed that 2-[18F]FELP is predominantly transported by the LAT1 transporter, decreas-
ing non-specific uptake. No significantly different TBRmean, TBRmax, SUVmean tumor and SUVmax tumor values 
could be observed in comparison to [18F]FET in the F98 GB rat model. However, in contrast to [18F]FDG PET, 
higher TBRs were found. Based on our results, 2-[18F]FELP is a promising new PET tracer for glioma or LAT1 
imaging.
Methods
General. Reagents and solvents of analytical grade have been obtained from standard commercial sources 
and were used directly without further purification. Moisture sensitive reactions were performed under an argon 
atmosphere. Reactions were carried out at ambient temperature, unless specified in the text. For analytical TLC, 
pre-coated F254 aluminum plates (Machery-Nagel®) were employed, which have been visualized by UV and 
developed with sulfuric acid-anisaldehyde spray/charring. For purification, flash column chromatography was 
performed using Davisil® (40–63 µm) silica or a Reveleris X2 (Grace/Büchi) automated Flash unit with pre-
packed cartridges. Exact mass was analyzed by means of a Waters LCT Premier XE™ Time of Flight (ToF) mass 
spectrometer with a standard electrospray (ESI) and modular Lockspray™ interface. Samples dissolved in an 
appropriate solvent system and infused in a MeCN/water (1:1) +0.1% formic acid mixture at 100 µL/min. NMR 
spectra were recorded on a Varian Mercury 300 MHz spectrometer. Chemical shifts (δ) are given in ppm and 
spectra are referenced to the residual solvent peak signal, with coupling constants (J) expressed in Hz. For 19F-
NMR, signals were referenced to the lock resonance frequency according to IUPAC referencing with CFCl3 set to 
0 ppm. Optical rotations were measured employing a Perkin Elmer 241 Polarimeter.
Chiral HPLC was performed using the specified chiral column (vide infra) from Diacel, 250 × 4.6 mm, 
particle size 5 µm. Column temperature was 35 °C. Runs were performed isocratically with a mixture of 
EtOH(abs.)/n-hexane as specified below, with a run length of 30 min at a flow rate of 1 mL/min.
Alternatively, chiral HPLC was performed (compounds 32 & 33, including 2-[18F]FELP) employing an Astec® 
Chirobiotic-T column (5 µm, 125 × 4.6 mm), operated at ambient temperature, with a mobile phase consisting of 
EtOH/water (8/2) at a flow rate of 1 mL/min.
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Chiral capillary electrophoresis (compounds 15 & 16 and 17 & 18) was performed using a 64.5 cm capillary 
(50 µm diameter). The electrolyte used consisted of 25 mM phosphate buffer pH 2.5 + 5% HS-gammaCD chiral 
modifier. Analysis time was 40 min at −20 kV.
Experimental procedures & compound characterization data. 1-(tert-butyl)-4-(4, 5, 6, 7-tetrachloro-1, 
3-dioxoisoindolin-2-yl)-(tert-butoxycarbonyl)-l-aspartate (1). 
Boc-L-aspartic acid 4-tert-butyl ester (0.29 g, 1.0 mmol, 1 eq.) was dissolved in anhydrous DCM (10 mL, 10 mL/
mmol SM). Then, DMAP (0.0012 g, 0.10 mmol, 0.1 eq.) and N-hydroxytetrachlorophthalimide (0.31 g, 1.0 mmol, 
1 eq.) were added, followed by DIC (0.175 mL, 1.10 mmol, 1.1 eq.). The resulting suspension was stirred under 
argon for approximately 2 h. Then, the mixture was filtered and evaporated. Purification by column chromatog-
raphy (0 → 10% EA/PET) gave 1 (0.34 g, 0.59 mmol) as a white solid in 59% yield. 1H-NMR (300 MHz, CDCl3) 
δ: 1.46 (s, 9H, tBu), 1.47 (s, 9H, tBu), 3.23 (dd, J = 17.4, 4.8 Hz, 1H, CH2), 3.32 (dd, J = 17.4, 4.8 Hz, 1H, CH2), 
4.57 (dt, J = 7.2, 4.8 Hz, 1H, CH), 5.47 (d, J = 7.5 Hz, 1H, NH). 13C NMR (75 MHz, CDCl3) δ: 27.9 (t-Bu, CH3), 
28.4 (tBu, CH3), 34.3 (CH2), 50.3 (CHNH), 80.5 (tBu-C-(CH3)3), 83.6 (tBu-C-(CH3)3), 124.8, 130.7, 141.3, 
155.5, 157.3, 167.2, 168.7. HRMS (ESI): calculated for C21H23Cl4N1O8 ([M + H]+): 571.0203, found: 571.0184. 
[α]20D = +37.76 (c 1.17, CHCl3).
Synthesis of 1-(tert-butyl) 4-(4, 5, 6, 7-tetrachloro-1, 3-dioxoisoindolin-2-yl) (tert-butoxycarbonyl)-d-aspartate (2). 
According to the procedure described for compound 1; Boc-D-aspartic acid 4-tert-butyl ester (0.87 g, 3.0 mmol) 
was transformed into 2 (1.2 g, 2.1 mmol) as a white solid in 70% yield. 1H-NMR (300 MHz, CDCl3) δ: 1.46 (s, 9H, 
tBu), 1.47 (s, 9H, tBu), 3.23 (dd, J = 17.4, 4.8 Hz, 1H, CH2), 3.32 (dd, J = 17.4, 4.8 Hz, 1H, CH2), 4.56 (dt, J = 7.2, 
4.8 Hz, 1H, CH), 5.46 (d, J = 7.5 Hz, 1H, NH). 13C NMR (75 MHz, CDCl3) δ: 27.9 (tBu, CH3), 28.4 (tBu, CH3), 
34.3 (CH2), 50.3 (CHNH), 80.5 (tBu-C-(CH3)3), 83.6 (tBu-C-(CH3)3), 124.8, 130.7, 141.3, 155.4, 157.3, 167.2, 




1 (0.477 g, 0.833 mmol, 1 eq.) and 21 (0.7 g, 2.5 mmol, 3 eq.) were placed in a 100 mL round bottom flask, 
equipped with a stir bar. The flask was evacuated and refilled with argon, three times. Then, anhydrous 1, 
4-dioxane (33.8 mL, 40 mL/mmol SM) and Et3N (1.16 mL, 8.33 mmol, 10 eq.) were added. The resulting mix-
ture was stirred at ambient temperature until a homogeneous solution was obtained (~5 to 10 min). Then, the 
flask was transferred into a pre-heated oil bath at 75 °C and stirred for another 5 min, after which the catalyst 
solution (3.4 mL, 4 mL/mmol SM) was added. The resulting solution was stirred at 75 °C overnight. After cool-
ing to ambient temperature, the solvents were removed in vacuo, and the residue taken up in EA/water. The 
layers were separated, and the water layer extracted twice with EA. The organic layers were combined, dried 
over Na2SO4, filtered and evaporated. The residue was purified by column chromatography (0 → 10% EA/PET) 
to give 3 (0.185 g, 0.386 mmol) as a yellowish oil in 46% yield. 1H-NMR (300 MHz, CDCl3) δ: −0.02 (s, 6H, 
Si-CH3), 0.87 (s, 9H, Si-tBu-CH3), 1.42 (s, 18H, tBu), 2.78 (t, J = 7.2 Hz, 2H, PhCH2CH2OTBS), 3.02 (d, J = 5.7 Hz, 
2H, PhCH2CHNH), 3.77 (t, J = 7.2 Hz, 2H, PhCH2CH2OTBS), 4.39–4.45 (m, 1H, CHNH), 4.94 (d, J = 7.8 Hz, 
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1H, NH), 7.06–7.13 (m, 4H, HPhe). 13C-NMR (75 MHz, CDCl3) δ: −5.2 (2C, Si-CH3), 18.5 (Si-C-(CH3)3), 26.1 
(3C, Si-C-(CH3)3), 28.1 (3C, tBu), 28.5 (3C, tBu), 38.1 (Ph-CH2CH), 39.4 (PhCH2CH2OTBS), 55.0 (CHNH), 
64.7 (PhCH2CH2OTBS), 79.7 (tBu-C-(CH3)3), 82.1 (tBu-C-(CH3)3), 129.4 (2C), 129.5 (2C), 134.2, 137.9, 155.2 
(C=OBoc), 171.1 (C=Oester). HRMS (ESI): calculated for C26H46NO5Si ([M + H]+): 480.3140, found: 480.3138. 
[α]20D = +26.78 (c 0.30, CHCl3).
Chiral HPLC: Chiralpak IA, eluent: n-Hexane/EtOH(abs.) (97/3), retention time: 5.36 min. ee: 100%.
Preparation of the catalyst solution (NiCl2.6H2O; 4, 4-di-t-butyl-bipyridine 0.05 M in DMF) was performed 
as has been described in literature30.
tert-butyl-(R)-2-((tert-butoxycarbonyl)amino)-3-(4-(2-((tert-butyldimethylsilyl)oxy)ethyl)phenyl)propanoate (4 
– d-type). 
According to the procedure described for 3; 2 (0.41 g, 0.71 mmol) was transformed into 4 (0.31 g, 0.65 mmol) 
as a colorless oil in 46% yield. 1H-NMR (300 MHz, CDCl3) δ: −0.02 (s, 6H, Si-CH3), 0.87 (s, 9H, Si-tBu-CH3), 
1.41 (s, 9H, tBu), 1.42 (s, 9H, tBu), 2.78 (t, J = 7.2 Hz, 2H, PhCH2CH2OTBS), 3.02 (d, J = 5.7 Hz, 2H, PhCH2CH), 
3.77 (t, J = 7.2 Hz, 2H, PhCH2CH2OTBS), 4.42 (dd, J = 13.8, 6.3 Hz, 1H, CHNH), 4.94 (d, J = 8.1 Hz, 1H, 
NHBoc), 7.05–7.13 (m, 4H, HPhe). 13C-NMR (75 MHz, CDCl3) δ: − 5.3 (2C, Si-CH3), 18.5 (Si-C-(CH3)3), 26.1 
(3C, Si-C-(CH3)3), 28.1 (3C, tBu), 28.5 (3C, tBu), 38.1 (Ph-CH2CH), 39.4 (PhCH2CH2OTBS), 55.0 (CHNH), 
64.7 (PhCH2CH2OTBS), 79.7 (tBu-C-(CH3)3), 82.1 (tBu-C-(CH3)3), 129.3 (2C), 129.5 (2C), 134.2, 137.8, 155.2 
(C=OBoc), 171.1 (C=Oester). HRMS (ESI): calculated for C26H46N1O5Si ([M + H]+): 480.3140, found: 480.3152. 
[α]20D = − 25.00 (c 0.56, CHCl3).
Chiral HPLC: Chiralpak IA, eluent: n-Hexane/EtOH(abs.) (97/3), retention time: 4.95 min. ee: 96.3%.
tert-butyl-(S)-2-((tert-butoxycarbonyl)amino)-3-(3-(2-hydroxyethyl)phenyl)propanoate (5 – l-type). 
According to the procedure as described for 3; 1 (0.57 g, 1.0 mmol) was transformed into 5 (0.28 g, 0.59 mmol) as 
a colorless oil in 59% yield.
1H-NMR (300 MHz, CDCl3) δ: -0.01 (s, 6H, Si-(CH3)2), 0.87 (s, 9H, Si-tBu-CH3), 1.40 (s, 9H, tBu), 1.42 (s, 
9H, tBu), 2.78 (t, J = 7.2 Hz, 2H, PhCH2CH2OTBS), 3.02 (d, J = 6.0 Hz, 2H, PhCH2CH), 3.77 (t, J = 7.5 Hz, 2H, 
PhCH2CH2OTBS), 4.40–4.57 (m, 1H, CHNHBoc), 4.96 (d, J = 7.8 Hz, 1H, NHBoc), 6.99 (s, 1H, Ph-H), 7.02–
7.09 (m, 2H, HPhe), 7.19 (t, J = 7.5 Hz, 1H, HPhe).13C-NMR (75 MHz, CDCl3) δ: −5.2 (2C, Si-CH3), 18.5 (Si-C-
(CH3)3), 26.1 (3C, Si-C-(CH3)3), 28.1 (tBu, CH3), 28.5 (tBu, CH3), 38.4 (PhCH2CH), 39.7 (PhCH2CH2OTBS), 
54.9 (CHNH), 64.7 (PhCH2CH2OTBS), 79.7 (tBu-C-(CH3)3), 82.1 (tBu-C-(CH3)3), 127.4, 127.8, 128.3, 130.5, 
136.4, 139.2, 155.2 (C=OBoc), 171.1 (C=Oester). HRMS (ESI): calculated for C26H46NO5Si ([M + H]+): 480.3140, 
found: 480.3142. [α]20D = +26.76 (c 0.36, CHCl3).
tert-butyl-(R)-2-((tert-butoxycarbonyl)amino)-3-(3-(2-hydroxyethyl)phenyl)propanoate (6 – d-type). 
According to the procedure as described for 3; 2 (0.57 g, 1.0 mmol) was transformed into 6 (0.16 g, 0.34 mmol) as 
a colorless oil in 34% yield.
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1H-NMR (300 MHz, CDCl3) δ: −0.01 (s, 6H, Si-(CH3)2), 0.87 (s, 9H, Si-tBu -CH3), 1.40 (s, 9H, tBu), 1.42 (s, 
9H, tBu), 2.78 (t, J = 7.5 Hz, 2H, PhCH2CH2OTBS), 3.03 (d, J = 6.0 Hz, 2H, PhCH2CH), 3.78 (t, J = 7.2 Hz, 2H, 
PhCH2CH2OTBS), 4.40–4.47 (m, 1H, CHNH), 4.95 (d, J = 7.8 Hz, 1H, NH), 6.95 (s, 1H, HPhe), 7.02–7.09 (m, 
2H, HPhe), 7.19 (t, J = 7.8 Hz, 1H, HPhe). 13C-NMR (75 MHz, CDCl3) δ: −5.2 (2C, Si-CH3), 18.5 (Si-C-(CH3)3), 
26.1 (3C, Si-C-(CH3)3), 28.1 (tBu), 28.5 (3C, tBu), 38.5 (PhCH2CH), 39.7 (PhCH2CH2OTBS), 54.9 (CHNH), 
64.7 (PhCH2CH2OTBS), 79.7 (tBu-C-(CH3)3), 82.1 (tBu-C-(CH3)3), 127.5, 127.8, 128.3, 130.5, 136.4, 139.2, 155.2 
(C=OBoc), 171.1 (C=Oester). HRMS (ESI): calculated for C26H46NO5Si ([M + H]+): 480.3140, found: 480.3183. 
[α]20D = +24.07 (c 0.26, CHCl3).
tert-butyl-(S)-2-((tert-butoxycarbonyl)amino)-3-(4-(2-hydroxyethyl)phenyl)propanoate (7 – l-type). 
3 (0.098 g, 0.204 mmol) was dissolved in THF (3 mL, 10 mL/mmol SM) and TBAF in THF (1.0 M, 0.23 mL, 
0.23 mmol, 1.1 eq.) was added. The resulting mixture was stirred for approximately 1H, and then sat. aq. NH4Cl 
solution was added together with EA. The layers were separated; the water layer extracted twice more with EA. 
The organic layers were combined and dried over Na2SO4, filtered and evaporated. The residue was purified 
by column chromatography (0 → 35% EA/PET) to give 7 (0.062 g, 0.17 mmol) as a colorless oil in 83% yield. 
1H-NMR (300 MHz, CDCl3) δ: 1.41 (s, 18H, tBu), 1.62 (br. s, 1H, OH), 2.84 (t, J = 6.6 Hz, 2H, PhCH2CH2OH), 
3.00–3.04 (m, 2H, PhCH2CH), 3.84 (t, J = 6.6 Hz, 2H, PhCH2CH2OH), 4.43 (dd, J = 14.1, 6.6 Hz, 1H, PhCH2CH), 
4.98 (d, J = 8.1 Hz, 1H, NH), 7.10–7.26 (m, 4H, HPhe). HRMS (ESI): calculated for C20H32NO5 ([M + H]+): 
366.2275, found: 366.2284. [α]20D = +42.23 (c 0.85, CHCl3). Spectral data matched those reported in literature25.
tert-butyl-(R)-2-((tert-butoxycarbonyl)amino)-3-(4-(2-hydroxyethyl)phenyl)propanoate (8 – d-type). 
According to the procedure as described for 7; 4 (0.326 g, 0.7 mmol) was transformed into 8 (0.196 g, 0.536 mmol) 
as a colorless oil in 77% yield. 1H-NMR (300 MHz, CDCl3) δ: 1.41 (s, 18H, tBu CH3), 2.84 (t, J = 6.6 Hz, 2H, 
PhCH2CH2OH), 2.96–3.08 (m, 2H, PhCH2CH), 3.84 (t, J = 6.6 Hz, 2H, PhCH2CH2OH), 4.39–4.46 (m, 1H, 
CHNH), 4.98 (d, J = 8.1 Hz, 1H, NH), 7.10–7.17 (m, 4H, HPhe). HRMS (ESI): calculated for C20H32NO5 
([M + H]+): 366.2275, found: 366.2282. Spectral data matched those reported in literature25.
tert-butyl (S)-2-((tert-butoxycarbonyl)amino)-3-(3-(2-hydroxyethyl)phenyl)propanoate (9 – l-type). 
According to the procedure as described for 7; 5 (0.547 g, 1.14 mmol) was transformed into 9 (0.29 g, 0.80 mmol) 
as a colorless oil in 71% yield. 1H-NMR (300 MHz, CDCl3) δ: 1.37 (s, 9H, tBu), 1.42 (s, 9H, tBu), 1.81 (br. s, 1H, 
OH), 2.82 (t, J = 6.3 Hz, 2H, PhCH2CH2OH), 2.92 (dd, J = 13.8, 6.9 Hz, 1H, PhCH2CH), 3.10 (dd, J = 13.8, 6.0 Hz, 
1H, PhCH2CH), 3.76–3.90 (m, 2H, PhCH2CH2OH), 4.47 (dd, J = 14.4, 6.9 Hz, 1H, CHNH), 4.98 (d, J = 8.7 Hz, 
1H, NH), 7.01–7.09 (m, 3H, HPhe), 7.22 (t, J = 7.8 Hz, 1H, HPhe). 13C-NMR (75 MHz, CDCl3) δ: 28.1 (3C, tBu), 
28.4 (3C, tBu), 39.0 (PhCH2CH), 39.3 (PhCH2CH2OH), 55.0 (PhCH2CH), 63.7 (PhCH2CH2OH), 79.8 (tBu-C-
(CH3)3), 82.2 (tBu-C-(CH3)3), 127.6, 128.0, 128.7, 130.5, 136.8, 138.8, 155.1 (C=OBoc), 171.2 (C=Oester). HRMS 
(ESI): calculated for C20H32NO5 ([M + H]+): 366.2275, found: 366.2268. [α]20D = +25.68 (c 0.51, CHCl3).
Chiral HPLC: Chiralpak IB, eluent: n-Hexane/EtOH(abs.) (97/3), retention time: 12.39 min. ee: 99.6%.
1 2Scientific RepoRts |          (2019) 9:2878  | https://doi.org/10.1038/s41598-019-40013-x
www.nature.com/scientificreportswww.nature.com/scientificreports/
tert-butyl-(R)-2-((tert-butoxycarbonyl)amino)-3-(3-(2-hydroxyethyl)phenyl)propanoate (10 – d-type). 
According to the procedure as described for 7; 6 (0.26 g, 0.54 mmol) was transformed into 10 (0.15 g, 0.40 mmol) 
as a colorless oil in 73% yield. 1H - NMR (300 MHz, CDCl3) δ: 1.37 (s, 9H, tBu), 1.44 (s, 9H, tBu), 1.94 (br. s, 1H, 
OH), 2.82 (t, J = 6.6 Hz, 2H, Ph-CH2CH), 2.92 (dd, J = 13.8, 6.9 Hz, 1H, PhCH2CH), 3.09 (dd, J = 13.8, 5.7 Hz, 
1H, PhCH2CH), 3.75–3.89 (m, 2H, PhCH2CH2OH), 4.46 (dd, J = 14.4, 6.9 Hz, 1H, CHNH), 4.99 (d, J = 8.1 Hz, 
1H, NH), 7.00–7.09 (m, 3H, HPhe), 7.21 (t, J = 7.8 Hz, 1H, HPhe). 13C-NMR (75 MHz, CDCl3) δ: 28.1 (3C, tBu), 
28.4 (3C, tBu), 38.9 (PhCH2CH), 39.3 (PhCH2CH2OH), 55.0 (PhCH2CH), 63.7 (PhCH2CH2OH), 79.8 (tBu-C-
(CH3)3), 82.2 (tBu-C-(CH3)3), 127.6, 127.9, 128.6, 130.5, 136.7, 138.8, 155.1 (C=OBoc), 171.1 (C=Oester). HRMS 
(ESI): calculated for C20H32N1O5 ([M + H]+): 366.2275, found: 366.2281. [α]20D = − 26.79 (c 0.52, CHCl3).
Chiral HPLC: Chiralpak IB, eluent: n-Hexane/EtOH(abs.) (97/3), retention time: 10.52 min. ee: 98.3%.
tert-butyl-(S)-2-((tert-butoxycarbonyl)amino)-3-(4-(2-fluoroethyl)phenyl)propanoate (11 – l-type). 
7 (0.18 g, 0.49 mmol, 1 eq.) was dissolved in anhydrous DCM (2.5 mL, 10 mL/mmol SM) under argon and cooled 
in an ice bath at 0 °C. Then, DAST (0.20 mL, 1.5 mmol, 3 eq.) was added dropwise and the resulting solution 
stirred at ambient temperature for 3–4 h. Then, the mixture was cooled to 0 °C in an ice bath and aq. sat. NaHCO3 
solution was added dropwise. After the gas evolution ceased, the mixture was transferred into a separatory funnel 
and more sat. aq. NaHCO3 solution was added. The layers were separated, and the water layer was extracted twice 
more with DCM. The organic layers were combined, dried over Na2SO4, filtered and evaporated till dryness. The 
resulting mixture was purified by column chromatography (0 → 12% EA/PET) to give 11 (0.076 g, 0.21 mmol) as 
a colorless oil in 42% yield. 1H-NMR (300 MHz, CDCl3) δ: 1.40 (s, 9H, tBu), 1.42 (s, 9H, tBu), 2.94 (t, J = 6.6 Hz, 
1H, PhCH2CH2F)*, 3.00–3.06 (m, 3H, PhCH2CH2F; PhCH2CH), 4.43 (q, J = 6.9 Hz, 1H, PhCH2CH), 4.60 (dt, 
J = 47.1, 6.6 Hz, 2H, PhCH2CH2F), 4.98 (d, J = 6.9 Hz, 1H, NH), 7.10–7.17 (m, 4H, HPhe). 19F-NMR (282 MHz, 
CDCl3) δ: −214.98 – −215.48 (m, 1F). Spectral data are in accordance with literature values25.
tert-butyl-(R)-2-((tert-butoxycarbonyl)amino)-3-(4-(2-fluoroethyl)phenyl)propanoate (12 – d-type). 
According to the procedure described for 11; 8 (0.174 g, 0.476 mmol) was transformed into 12 (0.065 g, 
0.18 mmol) as a colorless oil in 37% yield. 1H-NMR (300 MHz, CDCl3) δ: 1.40 (s, 9H, tBu), 1.42 (s, 9H, tBu), 2.98 
(dt, J = 23.1, 6.6 Hz, 2H, PhCH2CH2F), 3.00–3.04 (m, 2H, PhCH2CH), 4.43 (dd, J = 13.8, 6.3 Hz, 1H, PhCH2CH), 
4.60 (dt, J = 47.1, 6.9 Hz, 2H, PhCH2CH2F), 4.98 (d, J = 8.4 Hz, 1H, NH), 7.10–7.17 (m, 4H, HPhe). 19F-NMR 
(282 MHz, CDCl3) δ): −214.98 – −215.48 (m, 1 F). Spectral data matched those reported in literature25.
*This peak is in fact a doublet of triplets (F-coupling); however, the peak coincides with the PhCH2CH signal and was not sufficiently resolved for adequate 
calculation.
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tert-butyl-(S)-2-((tert-butoxycarbonyl)amino)-3-(3-(2-(tosyloxy)ethyl)phenyl)propanoate (13 – l-type). 
According to the procedure described for 11; 9 (0.235 g, 0.634 mmol) was transformed into 13 (0.117 g, 
0.319 mmol) as a colorless oil in 50% yield. 1H-NMR (300 MHz, CDCl3) δ: 1.40 (s, 9H, tBu), 1.42 (s, 9H, 
tBu), 2.98 (dt, J = 23.1, 6.6 Hz, 2H, PhCH2CH2F), 3.03 (dd, J = 6.3, 4.2 Hz, 2H, PhCH2CHNH), 4.41–4.48 
(m, 1H, PhCH2CH), 4.61 (dt, J = 47.1, 6.6 Hz, 2H, PhCH2CH2F), 4.98 (d, J = 7.8 Hz, 1H, NH), 7.04–7.12 (m, 
3H, HPhe), 7.22 (d, J = 7.8 Hz, 1H, HPhe). 19F-NMR (282 MHz, CDCl3) δ: −215.06 (tt, J = 46.8, 22.8 Hz, 1 F). 
13C-NMR (75 MHz, CDCl3) δ: 28.1 (3C, tBu), 28.5 (3C, tBu), 37.0 (d, J = 20.6 Hz, 1C, PhCH2CH2F), 38.6 
(PhCH2CHNHBoc), 54.9 (PhCH2CHNH), 79.8 (tBu-C-(CH3)3), 82.2 (t-Bu-C-(CH3)3), 84.1 (d, J = 168.2 Hz, 1C, 
PhCH2CH2F), 127.6, 128.0, 128.7, 130.4, 136.8, 137.2 (d, J = 5.7 Hz, 1C, Ph-C-CH2CH2F), 155.2 (C=OBoc), 171.1 
(C=Oester). HRMS (ESI): calculated for C20H31FNO4 ([M + H]+): 368.2232, found: 368.2231. [α]20D = +40.83 (c 
0.72, CHCl3).
tert-butyl-(R)-2-((tert-butoxycarbonyl)amino)-3-(3-(2-hydroxyethyl)phenyl)propanoate (14 – d-type). 
According to the procedure described for 11; 10 (0.146 g, 0.399 mmol) was transformed into 14 (0.042 g, 
0.11 mmol) as a colorless oil in 29% yield.
1H-NMR (300 MHz, CDCl3) δ: 1.40 (s, 9H, tBu), 1.42 (s, 9H, tBu), 2.95 (dt, J = 23.1, 6.6 Hz, 2H, PhCH2CH2F), 
3.01–3.05 (m, 2H, PhCH2CHNH), 4.45 (dd, J = 14.1, 6.3 Hz, 1H, PhCH2CHNH), 4.61 (dt, J = 47.1, 6.6 Hz, 2H, 
PhCH2CH2F), 4.99 (d, J = 8.1 Hz, 1H, NH), 7.04–7.12 (m, 3H, HPhe), 7.22 (d, J = 7.2 Hz, 1H, HPhe). 19F-NMR 
(282 MHz, CDCl3) δ: −215.02 (tt, J = 46.8, 22.8 Hz, 1 F). 13C-NMR (75 MHz, CDCl3) δ: 28.1 (3C, tBu), 28.5 (3C, 
tBu), 37.0 (d, J = 20.63 Hz, 1C, PhCH2CH2F), 38.5 (PhCH2CHNH), 54.9 (PhCH2CHNH), 79.8 (tBu-C-(CH3)3), 
82.2 (tBu-C-(CH3)3), 84.1 (d, J = 168.3 Hz, 1C, PhCH2CH2F), 127.6, 128.0, 128.7, 130.4, 136.8, 137.2 (d, J = 5.7 Hz, 
1C, Ph-C-CH2CH2F), 155.2 (C=OBoc), 171.1 (C=Oester). HRMS (ESI): calculated for C20H31FN1O4 ([M + H]+): 
368.2232, found: 368.2228. [α]20D = −40.24 (c 0.4, CHCl3).
(S)-2-amino-3-(4-(2-fluoroethyl)phenyl)propanoic acid (15 – l-type – 4FELP). 
11 (0.076 g, 0.21 mmol) was dissolved in DCM (3.0 mL) after which TFA (3.0 mL) was added. The resulting 
solution was stirred at ambient temperature for approximately 5 hours, after which it was evaporated till dry-
ness. Next, the residue was co-evaporated with MeOH three times. Then, the residue was dissolved in ~2 mL 
of MeOH and the pH was adjusted to pH 6–7, with diluted aq. NH3 solution, after which a white precipitate 
formed. The mixture was refrigerated overnight, and then the liquid was removed via pipette aspiration. The 
remaining solid was washed thrice with a minimal amount of ice-cold MeOH and dried by means of oil pump 
high vacuum to give 15 (0.017 g, 0.081 mmol) as a white powder in 39% yield. 1H-NMR (300 MHz, D2O) δ: 3.06 
(dt, J = 27.6, 6.3 Hz, 2H, PhCH2CH2F), 3.12 (dd, J = 14.4, 8.1 Hz, 1H, PhCH2CHNH2), 3.29 (dd, J = 14.7, 5.4 Hz, 
1H, PhCH2CHNH2), 3.99 (dd, J = 8.1, 5.4 Hz, 1H, PhCH2CHNH2), 4.67 (t, J = 6.0 Hz, 1H, PhCH2CH2F), 7.29–
7.37 (m, 4H, HPhe). 19F-NMR (282 MHz, D2O) δ: −214.75 (tt, J = 49.8, 29.4 Hz, 1 F). HRMS (ESI): calculated for 
C11H15FNO2 ([M + H]+): 212.1081, found: 212.1077.
Chiral CE: retention time: 32.6 min, ee: 98.5%.
1 proton signal is missing (PhCH2CH2F) as it resides under the HDO peak; therefore, the signal for δ = 4.67 
ppm is calculated on the visual triplet and not on the actual doublet of triplets (dt).
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(R)-2-amino-3-(4-(2-fluoroethyl)phenyl)propanoic acid (16 – d-type – 4-FEDP). 
According to the procedure as described for 15; 11 (0.065 g, 0.18 mmol) was transformed into 11 (0.013 g, 
0.062 mmol) as a white powder in 35% yield. 1H-NMR (300 MHz, D2O) δ: 3.06 (dt, J = 27.6, 6.0 Hz, 2H, 
PhCH2CH2F), 3.12 (dd, J = 14.7, 8.1 Hz, 1H, PhCH2CH), 3.29 (dd, J = 14.7, 5.4 Hz, 1H, PhCH2CHNH2), 3.99 
(dd, J = 8.1, 5.4 Hz, 1H, PhCH2CHNH2), 4.75 (dt, J = 47.1, 6.3 Hz, 2H, PhCH2CH2F), 7.29–7.37 (m, 4H, HPhe). 
19F-NMR (282 MHz, D2O) δ): −216.04 (tt, J = 44.8, 29.1 Hz, 1 F).
Chiral CE: retention time: 28.4 min, ee: 88.8%.
(S)-2-amino-3-(3-(2-fluoroethyl)phenyl)propanoic acid.HCl salt (17 – l-type – 3-FELP). 
13 (0.114 g, 0.310 mmol) was dissolved in DCM (3.0 mL) after which TFA (3.0 mL) was added. The resulting 
solution was stirred at ambient temperature for approximately 5 hours. Then, the mixture was evaporated till 
dryness. The mixture was co-evaporated with MeOH three times. Then, the residue was neutralized with diluted 
aq. NH3 and refrigerated. As no precipitate formed; the mixture was evaporated till dryness and dissolved in water 
(~5 mL); and the pH adjusted to pH 6. Then, the mixture was purified by RP-flash chromatography (4 g, C-18 
column, Büchi). Gradient: 100% water for 1 min, then linear gradient 0 → 20% EtOH/water in 15 min. Product 
containing fractions were pooled and most of the water was evaporated in vacuo; after which the residue was 
lyophilized. Then, the white powder was dissolved in water and diluted (~0.5 M) aq. HCl (~0.5 mL) was added 
and lyophilized again, which gave 17 (0.035 g, 0.14 mmol) as a white powder in 46% yield. 1H-NMR (300 MHz, 
D2O) δ: 3.06 (dt, J = 27.9, 6.0 Hz, 2H, PhCH2CH2F), 3.21 (dd, J = 14.4, 7.8 Hz, 1H, PhCH2CH), 3.35 (dd, J = 14.4, 
5.7 Hz, 1H, PhCH2CH), 4.28 (dd, J = 7.8, 5.7 Hz, 1H, PhCH2CH), 4.75 (dt, J = 46.8, 6.0 Hz, 2H, PhCH2CH2F), 
7.23–7.34 (m, 3H, HPhe), 7.41 (t, J = 7.5 Hz, 1H, HPhe). 19F-NMR (282 MHz, D2O) δ: −216.11 (tt, J = 46.8, 27.6 Hz, 
1 F). 13C-NMR (75 MHz, D2O) δ: 35.6 (PhCH2CH), 35.8 (d, J = 19.4 Hz, 1C, PhCH2CH2F), 54.5 (PhCH2CH), 85.1 
(d, J = 160.3 Hz, 1C, PhCH2CH2F), 127.6, 128.4, 129.3, 129.9, 134.5, 138.7 (d, J = 4.6 Hz, 1C, Ph-C-CH2CH2F), 
171.8 (C=O). HRMS (ESI): calculated for C11H15FNO2 ([M + H]+): 212.1081, found: 212.1046.
Chiral CE: retention time: 23.74 min, ee: 95.4%.
(R)-2-amino-3-(3-(2-fluoroethyl)phenyl)propanoic acid.HOAc salt (18 – d-type – 3-FEDP). 
14 (0.072 g, 0.20 mmol) was dissolved in DCM (2.0 mL) after which TFA (2.0 mL) was added. The resulting solu-
tion was stirred at ambient temperature for approximately 5 hours. Then, the mixture was evaporated till dry-
ness. The mixture was co-evaporated with MeOH three times. Then, the residue was neutralized with diluted aq. 
NH3 and refrigerated. As no precipitate formed; the mixture was evaporated till dryness and dissolved in water 
(~4 mL); and the pH adjusted to pH 6. Then, the mixture was purified by RP-flash chromatography (4 g, C-18 
column, Büchi). Gradient: 100% water for 1 min, then linear gradient 0 → 20% EtOH/water in 15 min. Product 
containing fractions were pooled and most of the water was evaporated in vacuo; after which the residue was 
lyophilized. Then, the white powder was dissolved in water and diluted (~0.5 M) aq. HOAc (~0.5 mL) was added 
and lyophilized again, which gave 18 (0.025 g, 0.092 mmol) as a white powder in 46% yield. 1H-NMR (300 MHz, 
D2O) δ: 1.97 (s, 3H, OAc), 3.06 (dt, J = 27.9, 6.3 Hz, 2H, PhCH2CH2F), 3.12 (dd, J = 15.0, 5.7 Hz, 1H, PhCH2CH), 
3.29 (dd, J = 14.7, 5.4 Hz, 1H, PhCH2CH), 4.00 (dd, J = 8.1, 5.1 Hz, 1H, PhCH2CH), 4.75 (dt, J = 47.1, 6.3 Hz, 2H, 
PhCH2CH2F), 7.21–7.32 (m, 3H, HPhe), 7.40 (t, J = 7.5 Hz, 1H, HPhe). 19F-NMR (282 MHz, D2O) δ: −215.90 (tt, 
J = 46.8, 27.6 Hz, 1 F). 13C NMR (75 MHz, D2O) δ: 22.5 (CH3-acetate), 35.8 (d, J = 19.5 Hz, 1C, PhCH2CH2F), 36.2 
(PhCH2CH), 55.9 (PhCH2CH), 85.1 (d, J = 161.48 Hz, 1C, PhCH2CH2F), 127.5, 128.2, 129.2, 129.8, 135.4, 138.6 
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(d, J = 4.6 Hz, 1C, Ph-C-CH2CH2F), 173.8 (C=O), 180.2 (C=O, acetate). HRMS (ESI): calculated for C11H15FNO2 
([M + H]+): 212.1081, found: 212.1079.
Chiral CE: retention time: 19.3 min, ee: 93.8%.
Synthesis of 4-bromophenethoxy(t-butyl)dimethylsilane (19) 2-(4-bromophenyl)-ethanol. 
(2.0 g, 10 mmol, 1 eq.) was dissolved in 20 mL anhydrous DMF (2 mL/mmol SM) under argon. Then, imidazole 
(1.7 g, 25 mmol, 2.5 eq.) and TBSCl (1.8 g, 12 mmol, 1.2 eq.) were added. The resulting solution was stirred at 
ambient temperature for 3H, after which water and diethylether were added. The layers were separated, and the 
water layer extracted twice with diethylether. The organic layers were combined, washed with brine and dried 
over Na2SO4, filtered and evaporated till dryness. The residue was purified by column chromatography (100% 
PET → 2.5% EA/PET) to give 19 (3.1 g, 9.8 mmol) as a colorless oil in 98% yield. 1H-NMR (300 MHz, CDCl3) δ: 
−0.02 (s, 6H, 2 × CH3), 0.87 (s, 9H, tBu CH3), 2.77 (t, J = 6.9 Hz, 2H, Ph-CH2), 3.78 (t, J = 6.9 Hz, 2H, CH2OSi), 
7.06–7.10 (m, 2H, HPhe), 7.38–7.41 (m, 2H, HPhe). Spectral data matched those reported in literature48.
Synthesis of 3-bromophenethoxy(tert-butyl)dimethylsilane (20). 
According to the procedure as described for 19; 3-(4-bromophenyl)-ethanol (3.0 g, 15 mmol) was transformed 
into 20 (4.73 g, 15.0 mmol) as a colorless oil in quantitative yield. 1H-NMR (300 MHz, CDCl3) δ: −0.03 (s, 6H, 
Si-(CH3)3), 0.87 (s, 9H, tBu), 2.78 (t, J = 6.9 Hz, 2H, PhCH2CH2O), 3.79 (t, J = 6.9 Hz, 2H, PhCH2CH2O), 7.12–
7.17 (m, 2H, HPhe), 7.32–7.35 (m, 1H, HPhe), 7.37–7.38 (m, 1H, HPhe). 13C-NMR (75 MHz, CDCl3) δ: −5.32 (2C, 
Si-CH3), 18.45 (Si-C-(CH3)3), 26.04 (3C, tBu), 39.26 (PhCH2CH2O), 64.14 (PhCH2CH2O), 122.35, 127.98, 129.32, 
129.86, 132.44, 141.89. Spectral data matched those reported in literature31.
Synthesis of (4-(2-((tert-butyldimethylsilyl)oxy)ethyl)phenyl)boronic acid (21). 
19 (1.9 g, 6.0 mmol, 1 eq.) was dissolved in anhydrous THF (30 mL, 5 mL/mmol SM) in a flame-dried round 
bottom flask under argon. The resulting solution was cooled to −78 °C. Then, nBuLi in hexanes (1.6 M, 4.5 mL, 
7.2 mmol, 1.2 eq.) was added dropwise (0.3 mL/min) at −78 °C. After the addition was complete the resulting 
solution was kept at –78 °C for 1H, after which B(OMe)3 (1.0 mL, 9.0 mmol, 1.5 eq.) was added all at once at 
−78 °C. The solution was stirred at −78 °C for 30 min, after which the cooling bath was removed, and the reac-
tion stirred at ambient temperature for another 2 h. Then, aq. sat. NH4Cl solution (18 mL, 3 mL/mmol SM) was 
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added and stirring continued for 5 min. The organic solvents were removed in vacuo, and DCM was added. The 
pH was adjusted till pH 1 with 3 M aq. HCl solution, and the layers were separated. The water layer was extracted 
twice with DCM. The organic layers were combined, dried over Na2SO4, filtered and evaporated till dryness. The 
residue was purified by column chromatography (15 → 50% EA/PET), to give 21 (0.71 g, 2.5 mmol) as a colorless 
oil in 42% yield. 1H-NMR (300 MHz, CDCl3) δ: 0.00 (s, 6H, 2 × Si-CH3), 0.89 (s, 9H, tBu), 2.91 (t, J = 6.9 Hz, 2H, 
PhCH2), 3.87 (t, J = 6.9 Hz, 2H, CH2-OSi), 7.35 (d, J = 7.8 Hz, 2H, HPhe), 8.15 (d, J = 8.1 Hz, 2H, HPhe). HRMS 
(ESI): calculated for C15H26BO5Si ([M + HCOO]−): 325.1648, found: 325.1660. Spectral data matched those 
reported in literature49.
(3-(2-((tert-butyldimethylsilyl)oxy)ethyl)phenyl)boronic acid (22). 
According to the procedure as described for 21; 20 (1.9 g, 6.0 mmol) was transformed into 22 (0.925 g, 3.30 mmol) 
as a colorless oil 55% yield. 1H-NMR (300 MHz, CDCl3) δ: 0.00 (s, 6H, 2 × Si-CH3), 0.88 (s, 9H, tBu), 2.95 (t, 
J = 7.2 Hz, 2H, PhCH2CH2OTBS), 3.80 (t, J = 6.9 Hz, 2H, PhCH2CH2OTBS), 7.20–7.29 (m, 2H, HPhe), 7.30–7.35 
(m, 2H, HPhe). Spectral data matched those reported in literature31.
tert-butyl (S)−3-(2-bromophenyl)-2-((tert-butoxycarbonyl)amino)propanoate (23 – l-type). 
(S)-3-(2-bromophenyl)-2-((tert-butoxycarbonyl)amino)propanoic acid (0.69 g, 2.0 mmol, 1eq.) was dissolved 
in DCM (20 mL, 10 mL/mmol) under argon. Next, tert-butyl 2, 2, 2-trichloroacetimidate (1.3 g, 6.0 mmol, 3 eq.) 
was added. The resulting solution was stirred at ambient temperature overnight, after which water was added. 
Then, the layers were separated, and the organic layer was washed with sat. aq. NaHCO3 solution. The organic 
layer was dried over Na2SO4, filtered and evaporated. The residue was pre-adsorbed onto Celite® and purified by 
column chromatography (8% EA/PET); which gave 23 (0.72 g, 1.8 mmol) as an oil that solidified upon standing 
in 90% yield. 1H-NMR (300 MHz, CDCl3) δ: 1.37 (s, 9H, tBu), 1.40 (s, 9H, tBu), 3.06 (dd, J = 13.8, 8.7 Hz, 1H, 
Ph-CH2), 3.25 (dd, J = 13.3, 6.0 Hz, 1H, Ph-CH2), 4.51–4.59 (m, 1H, CH), 5.06 (d, J = 7.8 Hz, 1H, NH), 7.06–7.23 
(m, 3H, HPhe), 7.54 (d, J = 7.8 Hz, 1H, HPhe). 13C-NMR (75 MHz, CDCl3) δ: 28.0 (t-Bu, CH3), 28.4 (tBu, CH3), 39.2 
(CH2), 54.1 (CHNH), 79.7 (tBu, C-(CH3)3), 82.2 (tBu, C-(CH3)3), 125.2, 127.4, 128.5, 131.5, 133.0, 136.7, 155.1 
(C=OBoc), 171.2 (C=Oester). HRMS (ESI): calculated for C18H27BrNO4 ([M + H]+): 400.1118, found: 400.1133. 
[α]20D = +6.03 (c 0.995, CHCl3).
tert-butyl (R)-3-(2-bromophenyl)-2-((tert-butoxycarbonyl)amino)propanoate (24 – d-type). 
According to the procedure as described for 23; (R)-3-(2-bromophenyl)-2-((tert-butoxycarbonyl)amino)propanoic 
acid (1.7 g, 5.0 mmol) was transformed in to 24 (1.4 g, 3.6 mmol) as a white solid in 72% yield. 1H-NMR (300 MHz, 
CDCl3) δ: 1.37 (s, 9H, tBu), 1.40 (s, 9H, tBu), 3.06 (dd, J = 14.1, 8.7 Hz, 1H, Ph-CH2), 3.25 (dd, J = 13.8, 6.0 Hz, 1H, 
Ph-CH2), 4.51–4.59 (m, 1H, CH), 5.06 (d, J = 8.4 Hz, 1H, NH), 7.07–7.12 (m, 1H, HPhe), 7.19–7.26 (m, 2H, HPhe), 7.54 
(d, J = 8.1 Hz, 1H, HPhe). 13C-NMR (75 MHz, CDCl3) δ: 28.0 (tBu, CH3), 28.4 (tBu, CH3), 39.2 (CH2), 54.1 (CHNH), 
79.7 (tBu, C-(CH3)3), 82.2 (tBu, C-(CH3)3), 125.2, 127.4, 128.5, 131.5, 133.0, 136.7, 155.1 (C=OBoc), 171.2 (C=Oester). 
HRMS (ESI): calculated for C18H27BrNO4 ([M + H]+): 400.1118, found: 400.1132. [α]20D = −5.62 (c 1.46, CHCl3).
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tert-butyl (S)-2-((tert-butoxycarbonyl)amino)-3-(2-vinylphenyl)propanoate (25 – l-type). 
23 (0.20 g, 0.50 mmol, 1 eq.), LiCl (0.065 g, 1.5 mmol, 3 eq.) and Pd(Ph3P)2Cl2 (0.018 g, 0.025 mmol, 0.05 eq.) 
were added to a flame-dried round bottom flask under argon. The air was removed and refilled with argon. This 
procedure was repeated for three times in total. Then, under argon, anhydrous degassed DMF (2.5 mL, 5 mL/
mmol) was added, followed by vinyl-Sn(nBu)3 (0.19 mL, 0.65 mmol, 1.3 eq.). The resulting mixture was stirred 
at 70 °C overnight. Then, the mixture was evaporated and re-dissolved in DCM and pre-adsorbed onto Celite®. 
Then, purification by column chromatography (0 → 10% EA/PET) gave 25 (0.089 g, 0.26 mmol) as an oil in 51% 
yield. 1H-NMR (300 MHz, CDCl3) δ: 1.36 (s, 9H, tBu), 1.40 (s, 9H, tBu), 3.07–3.16 (m, 2H, CH2), 4.39–4.47 (m, 
1H, CHNH), 5.00 (d, J = 7.8 Hz, 1H, NH), 5.34 (dd, J = 11.1, 1.5 Hz, Hvinyl), 5.67 (d, J = 17.4 Hz, 1H, Hvinyl), 7.04 
(dd, J = 17.4, 11.1 Hz, 1H, Hvinyl), 7.11–7.25 (m, 3H, HPhe), 7.50 (dd, J = 7.8, 1.8 Hz, 1H, HPhe). 13C-NMR (75 MHz, 
CDCl3) δ: 28.0 (tBu, CH3), 28.5 (tBu, CH3), 36.3 (CH2), 54.9 (CHNH), 79.8 (tBu, C-(CH3)3), 82.1 (tBu, C-(CH3)3), 
116.3 (vinyl-CH2), 126.1 (vinyl-CH), 127.34, 127.7, 130.8, 134.2, 134.6, 137.6, 155.1 (C=OBoc), 171.3 (C=Oester). 
HRMS (ESI): calculated for C20H30NO4 ([M + H]+): 348.2169, found: 348.2176. [α]20D = +10.71 (c 0.56, CHCl3).
tert-butyl (R)-2-((tert-butoxycarbonyl)amino)-3-(2-vinylphenyl)propanoate (26 – d-type). 
According to the procedure described for 25; 24 (0.605 g, 1.5 mmol) was transformed into 26 (0.38 g, 1.0 mmol) as 
a yellowish oil in 67% yield. 1H-NMR (300 MHz, CDCl3) δ: 1.35 (s, 9H, tBu), 1.40 (s, 9H, tBu), 3.07–3.16 (m, 2H, 
CH2), 4.43 (q, J = 7.2 Hz, 1H, CHNH), 5.00 (d, J = 7.5 Hz, 1H, NH), 5.34 (dd, J = 11.1, 1.5 Hz, 1H, vinyl-H), 5.67 
(dd, J = 17.4, 1.2 Hz, 1H, Hvinyl), 7.04 (dd, J = 17.4, 11.1 Hz, 1H, Hvinyl), 7.11–7.26 (m, 3H, HPhe), 7.50 (dd, J = 7.2, 
1.8 Hz, 1H, HPhe). 13C-NMR (75 MHz, CDCl3) δ: 28.0 (tBu, CH3), 28.4 (tBu, CH3), 36.3 (CH2), 54.9 (CHNH), 79.8 
(tBu-C-(CH3)3), 82.1 (tBu-C-(CH3)3), 116.3 (vinyl-CH2), 126.0 (vinyl-CH), 127.34, 127.7, 130.8, 134.2, 134.5, 
137.6, 155.1 (C=OBoc), 171.3 (C=Oester). HRMS (ESI): calculated for C20H30NO4 ([M + H]+): 348.2169, found: 
348.2170. [α]20D = −10.21 (c 0.48, CHCl3).
tert-butyl (S)-2-((tert-butoxycarbonyl)amino)-3-(2-(2-hydroxyethyl)phenyl)propanoate (27 – l-type). 
25 (0.33 g, 0.96 mmol, 1 eq.) was dissolved in anhydrous THF (10 mL, 10 mL/mmol SM) under argon. The result-
ing solution was cooled to 0 °C in an ice-bath. After 5 min, BH3 in THF (1 M in THF; 0.96 mL, 0.96 mmol, 1 eq.) 
was added. Then, the ice-bath was removed, and the resulting solution stirred at ambient temperature for 1 h. 
Then, NaBO3.H2O (0.48 g, 4.8 mmol, 5 eq.) was added, followed by water (10 mL, 10 mL/mmol SM). The mixture 
was vigorously stirred for 2 h. Next, sat. aq. NH4Cl was added together with EA. The layers were separated, and 
the water layer extracted twice more with EA. The organic layers were combined, dried over Na2SO4, filtered 
and evaporated till dryness. The residue was purified by column chromatography (0 → 30% EA/PET) to give 27 
(0.23 g, 0.64) as a colorless oil in 66% yield. 1H-NMR (300 MHz, CDCl3) δ: 1.35 (s, 9H, tBu), 1.38 (s, 9H, tBu), 2.28 
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(br. s, 1H, OH), 2.92–3.16 (m, 4H, Ph-CH2), 3.89 (t, J = 6.3 Hz, 2H, CH2OH), 4.49 (q, J = 7.2 Hz, 1H, CHNH), 5.18 
(d, J = 7.8 Hz, 1H, NH), 7.13–7.22 (m, 4H, HPhe). 13C-NMR (75 MHz, CDCl3) δ: 28.0 (tBu, CH3), 28.4 (tBu, CH3), 
35.8 (CH2), 36.8 (CH2), 54.8 (CHNH), 63.6 (CH2OH), 80.0 (tBu-C-(CH3)3), 82.2 (tBu-C-(CH3)3), 126.4, 127.3, 
130.0, 131.0, 135.4, 137.6, 155.2 (C=OBoc), 171.4 (C=Oester). HRMS (ESI): calculated for C20H32NO5 ([M + H]+): 
366.2275, found: 366.2278. [α]20D = +7.17 (c 0.60, CHCl3).
tert-butyl (R)-2-((tert-butoxycarbonyl)amino)-3-(2-(2-hydroxyethyl)phenyl)propanoate (28 – d-type). 
According to the procedure as described for 27; 26 (0.34 g, 0.99 mmol) was transformed into 28 (0.22 g, 0.60 mmol) as 
a colorless oil in 61% yield. 1H-NMR (300 MHz, CDCl3) δ: 1.35 (s, 9H, tBu), 1.38 (s, 9H, tBu), 2.33 (br. s, 1H, OH), 2.95 
(dd, J = 13.8, 6.6 Hz, 1H, PhCH2), 2.95 (dd, J = 13.8, 8.1 Hz, 2H, PhCH2), 3.13 (dd, J = 13.8, 6.9 Hz, 1H, PhCH2), 3.90 (t, 
J = 6.3 Hz, 2H, CH2OH), 4.45–4.53 (m, 1H, CHNH), 5.17 (d, J = 8.1 Hz, 1H, NH), 7.12–7.23 (m, 4H, HPhe). 13C-NMR 
(75 MHz, CDCl3) δ: 28.0 (tBu, CH3), 28.4 (tBu, CH3), 35.8 (CH2), 37.0 (CH2), 54.8 (CHNH), 63.6 (CH2OH), 80.0 
(tBu-C-(CH3)3), 82.3 (tBu-C-(CH3)3), 126.5, 127.3, 130.0, 131.1, 135.5, 137.6, 155.2 (C=OBoc), 171.4 (C=Oester). HRMS 
(ESI): calculated for C20H32NO5 ([M + H]+): 366.2275, found: 366.2260. [α]20D = -6.67 (c 0.48, CHCl3).
tert-butyl (S)-2-((tert-butoxycarbonyl)amino)-3-(2-(2-fluoroethyl)phenyl)propanoate (29 – l-type). 
27 (0.090 g, 0.25 mmol, 1 eq.) was dissolved in anhydrous DCM (2.5 mL, 10 mL/mmol SM) under argon and 
cooled in an ice bath at 0 °C. Then, DAST (0.10 mL, 0.74 mmol, 3 eq.) was added dropwise and the mixture was 
stirred at ambient temperature for approximately 3–4 h. Then, the mixture was cooled to 0 °C in an ice bath and 
aq. sat. NaHCO3 solution was added dropwise. After the gas evolution ceased, the mixture was transferred into 
a separatory funnel and more sat. aq. NaHCO3 solution was added. The layers were separated, and the water 
layer extracted twice more with DCM. The organic layers were combined, dried over Na2SO4, filtered and evap-
orated till dryness. The residue was purified by column chromatography (0 → 12% EA/PET) to give 29 (0.041 g, 
0.11 mmol) as a yellowish oil in 45% yield. 1H-NMR (300 MHz, CDCl3) δ: 1.37 (s, 9H, tBu), 1.40 (s, 9H, tBu), 
3.01–3.17 (m, 4H, PhCH2), 4.37–4.45 (m, 1H, PhCHNH), 4.63 (dt, J = 46.8, 6.9 Hz, 2H, CH2F), 5.03 (d, J = 8.4 Hz, 
1H, NH), 7.11–7.22 (m, 4H, HPhe). 19F-NMR (282 MHz, CDCl3) δ: −215.01 – −214.52 (m). 13C-NMR (75 MHz, 
CDCl3) δ: 28.0 (tBu, CH3), 28.4 (tBu, CH3), 33.6 (d, J = 20.6 Hz, 1C, PhCH2CH2F), 36.1 (PhCH2), 54.9 (CHNH), 
79.9 (tBu-C-(CH3)3), 82.2 (tBu-C-(CH3)3), 84.0 (d, J = 169.4 Hz, 1C, PhCH2CH2F), 126.9, 127.3, 130.1, 130.8, 
135.3 (Ph-C-CH2CHNH), 135.9 (d, J = 6.9 Hz, 1C, Ph-C-CH2CH2F), 155.2 (C=OBoc), 171.4 (C=Oester). HRMS 
(ESI): calculated for C20H31FNO4 ([M + H]+): 368.2232, found: 368.2220. [α]20D = +21.87 (c 0.48, CHCl3).
tert-butyl (R)-2-((tert-butoxycarbonyl)amino)-3-(2-(2-fluoroethyl)phenyl)propanoate (30 – d-type). 
According to the procedure as described for 29; 28 (0.185 g, 0.506 mmol) was transformed into 30 (0.101 g, 
0.273 mmol) as a colorless oil in 54% yield. 1H-NMR (300 MHz, CDCl3) δ: 1.36 (s, 9H, tBu), 1.39 (s, 9H, tBu), 
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2.97–3.19 (m, 4H, Ph-CH2), 4.37–4.44 (m, 1H, PhCHNH), 4.62 (dt, J = 47.1, 6.9 Hz, 2H, CH2F), 5.05 (d, 
J = 8.4 Hz, 1H, NH), 7.15–7.23 (m, 4H, HPhe). 19F-NMR (282 MHz, CDCl3) δ: −215.02 – −214.53 (m). 13C-NMR 
(75 MHz, CDCl3) δ: 28.0 (tBu, CH3), 28.4 (tBu, CH3), 33.6 (d, J = 20.6 Hz, 1C, PhCH2CH2F), 36.1 (PhCH2), 54.9 
(CHNH), 79.8 (tBu-C-(CH3)3), 82.2 (tBu -C-(CH3)3), 83.9 (d, J = 168.3 Hz, 1C, PhCH2CH2F), 126.9, 127.3, 130.0, 
130.7, 135.3 (Ph-C-CH2CHNH), 135.9 (d, J = 5.7 Hz, 1C, Ph-C-CH2CH2F), 155.2 (C=OBoc), 171.3 (C=Oester). 
HRMS (ESI): calculated for C20H32NO5 ([M + H]+): 366.2275, found: 366.2260. [α]20D = −22.40 (c 0.50, CHCl3).
tert-butyl (S)-2-((tert-butoxycarbonyl)amino)-3-(2-(2-(tosyloxy)ethyl)phenyl)propanoate (31 – l-type). 
27 (0.22 g, 0.60 mmol, 1 eq.) was dissolved in anhydrous DCM (6.0 mL, 10 mL/mmol SM), after which Et3N 
(0.252 mL, 1.81 mmol, 3 eq.) was added. Then, a catalytic amount of DMAP followed by tosylchloride (0.138 g, 
0.722 mmol, 1.2 eq.) were added, and the resulting solution stirred at ambient temperature for 2 h. Next, water 
was added, and the layers separated. The water layer was extracted twice with DCM. The organic layers were com-
bined, dried over Na2SO4, filtered and evaporated. The residue was purified by column chromatography (0 → 20% 
EA/PET) to give 31 (0.175 g, 0.337 mmol) as a colorless oil in 56% yield. 1H-NMR (300 MHz, CDCl3) δ: 1.35 (s, 
9H, tBu), 1.39 (s, 9H, tBu), 2.43 (s, 3H, CH3), 2.87–3.12 (m, 4H, PhCH2), 4.12–4.24 (m, 2H, CH2OTs), 4.30–4.37 
(m, 1H, CHNH), 4.99 (d, J = 8.4 Hz, 1H, NH), 7.05–7.16 (m, 4H, HPhe), 7.26–7.30 (m, 2H, HPhe-Ts), 7.68–7.72 (m, 
2H, HPhe-Ts). 13C-NMR (75 MHz, CDCl3) δ: 21.8 (CH3), 28.0 (tBu, CH3), 28.4 (tBu, CH3), 32.1 (PhCH2CH2OTs), 
36.0 (PhCH2CH), 54.8 (PhCH2CH), 70.3 (PhCH2CH2OTs), 79.9 (tBu-C-(CH3)3), 82.3 (tBu-C-(CH3)3), 127.1, 
127.4, 128.0, 129.95, 130.04, 130.8, 133.2, 135.0, 135.3, 144.8, 155.1 (C=OBoc), 171.21 (C=Oester). HRMS (ESI): 
calculated for C27H28NO7S ([M + H]+): 520.2363, found: 520.2375. [α]20D = +11.06 (c 1.09, CHCl3).
(S)-2-amino-3-(2-(2-fluoroethyl)phenyl)propanoic acid (32 – l-type, 2-FELP). 
29 (0.090 g, 0.25 mmol) was dissolved in DCM (3.0 mL) after which TFA (3.0 mL) was added. The resulting solu-
tion was stirred at ambient temperature for approximately 5 hours, after which it was evaporated till dryness. Next, 
the residue was co-evaporated with MeOH three times. Then, the residue was dissolved in ~2 mL of MeOH and the 
pH was adjusted to pH 6–7, with diluted aq. NH3 solution, after which a white precipitate formed. The mixture was 
refrigerated overnight, and then the liquid was removed via pipette aspiration. The remaining solid was washed thrice 
with a minimal amount of ice-cold MeOH and dried under high vacuum to give 2-FELP (0.012 g, 0.057 mmol) as a 
white powder in 23% yield. 1H-NMR (300 MHz, D2O) δ: 3.10 (dd, J = 14.7, 9.0 Hz, 1H, PhCH2CH), 3.15 (dt, J = 26.4, 
6.0 Hz, 2H, PhCH2CH2F), 3.43 (dd, J = 14.7, 6.0 Hz, 1H, PhCH2CH), 3.95 (dd, J = 9.0, 6.0 Hz, 1H, PhCH2CH), 4.77 (dt, 
J = 47.4, 6.0 Hz, 2H, PhCH2CH2F), 7.31–7.43 (m, 4H, HPhe). 19F-NMR (282 MHz, D2O) δ: −218.58 (tt, J = 46.8, 26.5 Hz, 
1 F). 13C-NMR (75 MHz, D2O) δ: 32.4 (d, J = 19.4 Hz, 1C, PhCH2CH2F), 33.5 (PhCH2CH), 55.6 (PhCH2CH), 85.0 
(d, J = 161.4 Hz, 1C, PhCH2CH2F), 127.3, 128.0, 130.3, 130.4, 134.0, 136.5 (d, J = 4.6 Hz, 1C, Ph-C-CH2CH2F), 173.9 
(C=O). HRMS (ESI): calculated for C11H15FNO2 ([M + H]+): 212.1081, found: 212.1078.
Chiral HPLC: Astec® Chirobiotic T column (5 µm, 125 mm × 4.6), EtOH(abs.)/H2O (80/20), retention time: 
4.01 min, ee: 90.4%.
(R)-2-amino-3-(2-(2-fluoroethyl)phenyl)propanoic acid.HCl salt (33 – d-type, 2-FEDP). 
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30 (0.090 g, 0.25 mmol) was dissolved in DCM (3.0 mL) after which TFA (3.0 mL) was added. The resulting solu-
tion was stirred at ambient temperature for approximately 5 hours, after which it was evaporated till dryness. 
Next, the residue was co-evaporated with MeOH three times. Then, the residue was dissolved in ~2 mL of MeOH 
and the pH was adjusted to pH 6–7, with diluted aq. NH3 solution, after which a white precipitate formed. The 
mixture was refrigerated overnight, and then the liquid was removed via pipette aspiration. The remaining solid 
was washed once with a minimal amount of ice-cold MeOH and re-dissolved in MeOH. Then, 1.25 M HCl in 
MeOH was added and the mixture evaporated till dryness. The residue was dissolved in water and lyophilized, 
which gave rise to 34 (0.030 g, 0.12 mmol) as a white, amorphous powder in 49% yield. 1H-NMR (300 MHz, 
D2O) δ: 3.14 (dt, J = 26.7, 6.0 Hz, 2H, PhCH2CH2F), 3.13–3.21 (m, 1H, PhCH2CH), 3.48 (dd, J = 14.7, 6.3 Hz, 
1H, PhCH2CH), 4.13–4.19 (m, 1H, PhCH2CH), 4.77 (dt, J = 47.1, 6.0 Hz, 2H, PhCH2CH2F), 7.31–7.44 (m, 4H, 
HPhe). 19F-NMR (282 MHz, D2O) δ: −216.10 (tt, J = 46.8, 26.5 Hz, 1 F). 13C-NMR (75 MHz, D2O) δ: 32.35 (d, 
J = 19.4 Hz, 1C, PhCH2CH2F), 33.1 (PhCH2CH), 54.4 (PhCH2CH), 85.0 (d, J = 161.4 Hz, 1C, PhCH2CH2F), 127.4, 
128.2, 130.3, 130.4, 133.4, 136.6 (d, J = 4.6 Hz, 1C, Ph-C-CH2CH2F), 172.4 (C=O). HRMS (ESI): calculated for 
C11H15FNO2 ([M + H]+): 212.1081, found: 212.1085.
Chiral HPLC Astec® Chirobiotic T column (5 µm, 125 mm × 4.6), EtOH(abs.)/H2O (80/20), retention time: 
5.21 min, ee: 75.2%.
In vitro experiments. General information. The F98 GB cell line was obtained from ATCC and cultivated 
as described previously11. Cells were tested and authenticated by the provider and were cultured for maximum ten 
weeks after retrieval from liquid nitrogen.
LAT1 expression was determined using flow cytometry. F98 cells (100,000 per well) were surface stained with 
a monoclonal antibody against LAT1 (PE-conjugated, Santa Cruz biotechnology, Heidelberg, Germany), which 
acts as a negative control. As described by De Munter et al.50, cells were subsequently fixed, permeabilized and 
submitted for intracellular staining with the same PE conjugated monoclonal antibody against LAT1. Flow cyto-
metric analysis was performed using the LSR II (BD Biosciences).
In vitro experiments were carried out in 24-well-plates (VWR, US), using at least three wells for each data-point. 
The cells were seeded 24 h prior to the experiment at 200,000 cells/well. Influx of radiolabeled AA was studied in a 
Na+ containing buffer (HEPES+ buffer: pH 7.4; 100 mM NaCl (Sigma Aldrich, Belgium), 2 mM KCl (Sigma Aldrich, 
Belgium), 1 mM MgCl2 (VWR, US), 1 mM CaCl2 (VWR, US), 10 mM Hepes (Sigma Aldrich, Belgium), 5 mM 
Tris (VWR, US), 1 g/L glucose (VWR, US) and 1 g/L Bovine Serum Albumin (Sigma Aldrich, Belgium)) and/or a 
Na+ free buffer (HEPES- buffer: pH 7.4; 100 mM Choline-Cl (Sigma Aldrich, Belgium), 2 mM KCl, 1 mM MgCl2, 
1 mM CaCl2, 10 mM Hepes, 5 mM Tris, 1 g/L glucose and 1 g/L Bovine Serum Albumin). The culture medium was 
removed, and cells were washed twice with 1 mL HEPES+/HEPES- buffer. Dosing solutions were prepared by sup-
plementing the washing buffer with either 11 kBq [2, 3, 4, 5, 6-3H]-l-phenylalanine (Perkin Elmer, Massachusetts, 
USA)/mL or with 37 kBq of the [18F]-labelled AA. The incubation process was terminated by cooling the plates on 
ice and adding 1 mL 1% BSA ice-cold PBS. Cells were washed twice with 2 mL ice-cold PBS. Subsequently, cells 
were lysed with 250 µL 0.1 M NaOH (VWR, US) and radioactivity stemming from the [18F]-isotope was counted 
by subjecting 150 µL of this solution to an automated gamma-counter (Cobra-inspector 5003, Canberra Packard, 
Meriden, CT, USA). [3H] samples (150 µL) were transferred to a scintillation bottle (Perkin Elmer, Massachusetts, 
USA) containing 5 mL of scintillation liquid (Ultima Gold, Perking Elmer, Massachusetts, USA) and counted using 
an automated scintillation counter (TriCarb 2900 TR; Perkin Elmer, Massachusetts, USA). Of each well, 25 µL was 
subjected to a BCA assay (ThermoFisher Scientific) to determine protein content.
Concentration dependency using [2, 3, 4, 5, 6-3H]-l-phenylalanine. Non-linear curve fitting was performed to 
determine the Michaelis-Menten kinetics using Graphpad Prism v5.01 (Graphpad software, San Diego, CA, 
USA). These were employed to study the potential inhibition of the AA analogue towards the [3H]-l-Phe/l-Phe 
couple with varying concentrations (0.01 to 0.5 mM) at 1 min uptake (V0 conditions). The apparent Km and cor-
responding Ki values were calculated according to the formula:
= −Ki I Km Km[ ]/(( / ) 1)app
where [I] is the inhibitor concentration (i.e. the fluorinated AA), Km is the Michaelis-Menten constant of the 
substrate (i.e. ³H-l-Phe/l-Phe) and Km,app is the apparent value of Km for substrate transport in the presence of 
the inhibitor.
Radiochemical synthesis and purification. The radiofluorinated AA analogues, [18F]FET and 2-(2-
[18F]fluoroethyl)-l-phenylalanine (2-[18F]FELP) were prepared on a Synthra RN plus module (Synthra GmbH, 
Hamburg, Germany) with an integrated semi-preparative HPLC, using identical reaction and purification con-
ditions for both tracers, based on the method described by Bourdier et al.51 (depicted in Supplementary Fig. 1). 
The precursor solution for radiolabeling was prepared by dissolving 6 mg tert-butyl (S)-3-(4-(2-(tosyloxy)ethoxy)
phenyl)-2-(tritylamino)propanoate (ABX, Germany) or 9 mg tert-butyl (S)-2-((tert-butoxycarbonyl)amino)-3-
(2-(2-(tosyloxy)ethyl)phenyl)propanoate in 1 mL acetonitrile (Sigma Aldrich, Belgium). The precursor solution 
was added to a dried [18F]F−/Kryptofix®222/K+ complex, heated at 100 °C for 15 min. Subsequently, deprotection 
was performed by adding 2 M HCl (1 mL) for 15 min. The solution was then neutralized with 4 M NaOH, followed 
by adding 0.10 M NH4OAc. HPLC purification was performed using a RP symmetry Prep C18 column (5 µm, 
10 × 250 mm, Machery-Nagel, Duren, Germany), a 0.01 M NH4OAc buffer in ethanol/water 5/95 (V/V) mobile 
phase, and a flow rate of 5 mL/min. The fraction containing purified [18F]FET or 2-[18F]FELP eluted at approxi-
mately 12 min and 15 min respectively (depicted in Supplementary Figs 2 and 3 for [18F]FELP), and was collected 
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for 2 minutes. This procedure yielded in 3.32 ± 1.16 GBq [18F]FET or 3.01 ± 0.97 MBq 2-[18F]FELP. Quality 
control of the final formulation was performed by radio-TLC using Polygram TLC stripes (Macherey-Nagel, 
Germany), a mobile phase consisting of ACN/H2O 95/5 (V/V), and miniGITA (Raytest, Germany) analysis soft-
ware. Radiochemical purities of ≥95% were obtained for [18F]FET and for 2-[18F]FELP. Chiral purity of [18F]
FELP was assessed as described for the unlabelled amino acid.
1 MBq of 2-[18F]FELP or 2-[18F]FET was added to a 1:1 v:v mixture of MilliQ water and n-octanol in a test 
tube. After vortexing and centrifugation (10 min; 1100 g) of the samples, aliquots were taken from each layer and 
counted separately in a NaI (Tl) scintillation counter (Capintec; Ramsey, NJ, USA). The partition coefficient was 
calculated using the ratio of activity detected in n-octanol and in the aqueous layer to obtain the logPoct value.
Concentration and time dependency using 2-[18F]FELP or [18F]FET. Concentration dependency was meas-
ured at V0 conditions with concentrations of the AA varying from 0.01 to 0.5 mM. The data were fitted to the 
Michaelis-Menten model and the Km was calculated.
The cells were incubated for times ranging from 1–60 min in 250 µL of HEPES+ buffer supplemented with 
37 kBq of 2-[18F]FELP or [18F]FET.
To determine the selectivity of the LAT1 transporter for the fluor-18 labelled AA, the in vitro uptake was 
studied in the presence of Na+-rich or Na+-free buffer(HEPES+/− buffer), 8 mM of the system L and b0,+ inhib-
itor 2-aminobicycloheptane-2-carboxylic acid (BCH) (Sigma Aldrich, Belgium), 8 mM of the system A inhibitor 
methylaminoisobutyric acid (MeAiB) (Sigma Aldrich, Belgium) or 5 mM of the LAT1 specific inhibitor JPH-203 
(ARK Pharm, USA). The uptake studies supplemented with the transporter specific inhibitors were carried out 
in HEPES+ buffer.
In vivo experiments. The study was performed in accordance with the appropriate guidelines and regulations 
and approved by the Ghent University Ethical Committee on animal experiments (ECD15/39). The GB F98 rat 
model was developed as described by Bolcaen et al.11. Six female NIH-Foxn1rnu rats were inoculated with ±20,000 
F98 tumor cells in the right frontal lobe. The rats were anesthetized with ketamine/xylazine (4/3; 0.13 ml/100 g) 
and were kept separately post-inoculation (p.i.).
Tumor growth was evaluated 8 days p.i. using MRI (7T PharmaScan 70/16, Bruker BioSpin, Ettlingen, 
Germany). The rats were anesthetized with 2% isoflurane mixed with oxygen administered at a flow rate of 0.3 L/
min. After fixation, a heated blanket was placed on the animal. A rat brain surface coil (Rapid Biomedical, Rimpar, 
Germany) was placed around the head, after which the holder was positioned in a 72 mm rat whole body trans-
mitter coil (Rapid Biomedical, Rimpar, Germany). After performing a localizer scan, a T2-weighted spin-echo 
scan (TR/TE 3661/37.1 ms, 109 μm isotropic in plane resolution, 4 averages, TA 9′45″) was obtained. If a tumor 
was visible, a gadolinium-containing contrast agent (Dotarem, Guerbet, France; 0.4 mL/kg) was injected intra-
venously through a 30-Gauge needle connected to a 60 cm long PE tube into the tail vein. A contrast-enhanced 
T1-weighted spin-echo sequence (TR/TE 1539/9.7 ms, 117 µm isotropic in plane resolution, 3 averages, TA 4′15″) 
was performed 15 min post injection of the contrast agent.
When the presence of a tumor was confirmed, additional contrast-enhanced T1-weighted spin-echo scans 
were obtained, as above-mentioned. Post-MRI dynamic PET scans were acquired using 2-[18F]FELP, [18F]FET 
and [18F]FDG on three consecutive days (day 13, 14 and 15 p.i.). The total acquisition time was 120 min for both 
dynamic AA PET scans and 60 min for the dynamic [18F]FDG PET ([18F]FDGearly). In addition, a static 30 min 
[18F]FDG PET was acquired 240 min post-injection ([18F]FDGlate).
All PET scans were reconstructed into a 200 × 200 × 128 matrix by a 3D Maximum Likelihood Expectation 
Maximization (MLEM) algorithm (LabPET Version 1.12.1, TriFoil Imaging®, Northridge CA) using 50 iterations 
and a voxel size of 0.5 × 0.5 × 0.59675 mm. The dynamically acquired PET data were reconstructed into different 
time frames. Time frames were 6 × 20 s, 3 × 1 min, 3 × 5 min and 2 × 20 min for [18F]-FDG scans and 6 × 20 s, 
3 × 1 min, 3 × 5 min and 5 × 20 min for the AA PET.
Rigid body PET-MRI co-registration was done using PMOD (PMOD technologies®, Zürich, Switzerland) and 
volumes of interest (VOI) were manually drawn, including the contrast-enhanced region on T1-weighted MRI. 
Cubic VOIs of 2 × 2 × 2 mm located in the contralateral region were used as a reference. Tracer uptake in the VOI 
at each time frame was converted to a standard uptake value (SUV) according to the following formula:
= ×SUV (Radioactivity in VOI/injected activity) body weight
Injected activity was corrected for radioactive decay and residual activity in the syringe. Standardized uptake 
values (SUVmean and SUVmax) and tumor-to-background ratios (TBRmean and TBRmax) were calculated.
Data analysis. All data are expressed as means ± SD. All curves were constructed using GraphPad Prism 
5.0 (GraphPad Software, San Diego, CA, USA). Where applicable, statistical analysis was performed using the 
Mann-Whitney U test. A probability value of p < 0.05 was considered statistically significant.
Data Availability
All data generated or analyzed during this study are included in this published article (and its supplementary 
information file).
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